Australia's Osteopore advances on regulatory win in China's Hainan

Osteopore

26/05/2026 05:48

** Shares of Osteopore OSX.AX rise as much as 66.7% to A$0.01, their highest level since February 13

** Stock logs largest intraday pct gain since mid January

** Regenerative medicine firm receives approval from China's Hainan Medical Products Association for the clinical use of co's orthopaedic medical devices at Hainan branch hospital of Shanghai Ruijin Hospital

** Says Hainan regulatory approval is a licence that enables co to sell and market its devices in the Boao Lechang International Medical Tourism Pilot Zone, China's strategic and only special medical zone

** More than 72.5 million shares change hands, 30.9 times the 30-day average

** Stock up 23.1% YTD, including the day's moves

 (Reporting by Nikita Maria Jino in Bengaluru)

 ((Nikita.Jino@thomsonreuters.com;))